Tempus’ Patient-Derived Organoid (PDO) Screens

Evaluate the efficacy of your preclinical drug candidates across a range of therapeutic modalities—including small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), etc.

Currently enrolling panels:

• PanCancer: 60 PDOs across 12 indications (option to enroll in the full panel or a subset of 30 PDOs across 6 indications)
• PanCRC: 40 CRC PDOs enriched for pre-treated models
• PanPIK3CA: 30 PDOs enriched for PIK3CA mutations and CNVs

Key insights:

• Viability assessments, including IC50 and EC50 analyses, via luminescence readouts
• Responses to indication- or biomarker-specific standard-of-care (SOC) therapies
• Molecular insights, including Differential Gene Expression (DGE)
• Gene Set Enrichment Analysis (GSEA) to identify DNA/RNA drivers of response or resistance

Enrollment is open through March 30, 2026. Space is limited—complete the form now to secure your spot.